anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
PURPOSE: Surgical repair of complex abdominal wall hernias remains technically demanding and is widely recognized as a risk factor for unfavorable outcomes with high recurrence and morbidity rates. The objective is to assess short- and long-term complications after open intraperitoneal onlay mesh (IPOM) repair combined with bilateral anterior component separation (ACS) for large and difficult incisional hernias, alongside evaluating hernia recurrence rates.
METHODS: This retrospective analysis utilized data sourced from Hospital electronic health records and a prospective database at an academic tertiary referral center. Data collection was carried out from patients operated between January 2006 and December 2017. Eligible patients had complex incisional hernias measuring at least 10 cm in their transverse diameter and had an open IPOM repair with bilateral ACS.
RESULTS: In our study group of 45 patients, the 30-day surgical site occurrence (SSO) rate was high (37.8%), primarily consisting of superficial postoperative complications as seroma (17.8%) and wound dehiscence (6.7%). Among six patients (13.3%), wound complications escalated to chronic infected mesh-related problems, leading to complete mesh removal in four cases (8.9%) and partial mesh removal in two cases (4.4%). Regarding long-term complications, five patients (11.1%) developed enterocutaneous fistula. The recurrence rate was modest [5 out of 41 (12.2%)] over a median follow-up period of 99 months.
CONCLUSIONS: Despite a high SSO rate, application of the open IPOM technique with ACS could serve as a valuable rescue option for managing large and complex hernias, with acceptable hernia recurrence rates at long-term follow-up.
The combination of pharmacological and physical barrier therapy is a highly promising strategy for treating intrauterine adhesions (IUAs), but there lacks a suitable scaffold that integrates good injectability, proper mechanical stability and degradability, excellent biocompatibility, and non-toxic, non-rejection therapeutic agents. To address this, a novel injectable, degradable hydrogel composed of poly(ethylene glycol) diacrylate (PEGDA), sodium alginate (SA), and l-serine, and loaded with platelet-rich plasma (PRP) (referred to as PSL-PRP) is developed for treating IUAs. l-Serine induces rapid gelation within 1 min and enhances the mechanical properties of the hydrogel, while degradable SA provides the hydrogel with strength, toughness, and appropriate degradation capabilities. As a result, the hydrogel exhibits an excellent scaffold for sustained release of growth factors in PRP and serves as an effective physical barrier. In vivo testing using a rat model of IUAs demonstrates that in situ injection of the PSL-PRP hydrogel significantly reduces fibrosis and promotes endometrial regeneration, ultimately leading to fertility restoration. The combined advantages make the PSL-PRP hydrogel very promising in IUAs therapy and in preventing adhesions in other internal tissue wounds.
PURPOSE: To discriminate the data from plural kinds of measuring apparatuses without carrying out a complicated operation, and to easily read them by selecting a display surface input evaluation mode, an organism data discriminating mode, and an organism data reading mode, in order from the incorporated image data by a data recognizing means, so as to obtain an organism data. CONSTITUTION: An organism data display device such as an electronic clinical thermometer 10 is provided at a setting part 3, and the starting button of a console 4 is pushed. As a result, a luminous means emits the light, and an image incorporating operation is started under the control by a data recognizing means 5. The image data incorporated by an incorporating part 2 is delivered to the data recognizing means 5. The data recognizing means 5 carries out an organism data recognizing process depending on the decisions of modes 201 to 203.  The display surface input evaluation mode 201 is a mode where the process in carried out at first, the organism data discriminating mode 202 is a mode where the kind of the organism data displayed in the organism data display device is discriminated, and the organism data reading mode 203 is a mode where the characters and the figures are read from an image data 205.
PURPOSE: To obtain a makeup cosmetic excellent in makeup sustainability by formulating specific water-absorbing powder in organopolysiloxane elastomer spherical powder having a specific particle diameter. CONSTITUTION: This makeup cosmetic contains 0.1-20wt.% of organopolysiloxane elastomer spherical powder 1.0-15.0μm in average particle diameter and 0.1-20wt.% of water-absorbing polymeric powder (pref. calcium alginate powder). The organopolysiloxane elastomer spherical powder can be readily available from the relevant products being on the market (e.g. pref. Torayfil-E-506C (R)).
OBJECTIVES: To assess the correlation between the response to transcutaneous tibial nerve stimulation (TTNS) and subsequent response to sacral nerve modulation (SNM) to treat overactive bladder (OAB).
MATERIALS AND METHODS: All patients who consecutively received TTNS followed by a two-stage SNM between January 2016 and June 2022 to treat OAB in two university hospital centers were included. The response to each therapy was evaluated with success defined by a 50% or greater improvement in one or more bothersome urinary symptoms from baseline. The primary endpoint was the statistical relationship between the response to TTNS and the response to SNM, assessed by logistic regression. Secondary endpoints were the statistical relationship between the response to TTNS and the response to SNM when controlling for gender, age (<57 years vs. >57 years), presence of an underlying neurological disease, and presence of DO, adding the factor and interaction to the previous regression model.
RESULTS: Among the 92 patients enrolled in the study, 68 of them were women (73.9%), and the median age was 57.0 [41.0-69.0] years. The success was reported in 22 patients (23.9%) under TTNS and 66 patients (71.7%) during the SNM test phase. There was no statistical correlation between response to TTNS and response to SNM in the overall population (confidence interval: 95% [0.48-4.47], p = 0.51). Similarly, there was no statistical correlation when controlling for age <57 years or ≥57 years, with p = 1.0 and p = 0.69, respectively. No statistical study could be conducted for the other subpopulations due to small sample sizes.
CONCLUSION: The response to TTNS does not predict the response to SNM in the treatment of OAB. TTNS and SNM should be considered as separate therapies, and the decision-making process for OAB treatment should take this into account.
Uterine fibroids (UFs), the most common tumors in women of reproductive age, are characterized by sex steroid-dependent growth and excessive deposition of extracellular matrix (ECM) surrounding UF smooth muscle cells. Women with symptomatic UFs experience heavy menstrual bleeding and consequent iron-deficiency anemia. They also have a risk of recurrent pregnancy loss, preterm birth, and cesarean delivery, indicating that UFs can negatively affect reproductive outcomes. Various types of immune cells, including innate and adaptive cells, are observed in UFs; however, the impact of these cells on the pathophysiology of UFs remains unclear. Inflammation may play important roles in the growth of UFs, and expression levels of proinflammatory and inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-10, TNF-α, and TGF-β, are upregulated in UFs. These cytokines play important roles in the interaction between growth factors and ECM that is regulated by the sex steroids estrogen and progesterone. Furthermore, proinflammatory mediators are upregulated in females with UFs, with higher expression levels in the endometrium with submucosal and intramural UFs than in the endometrium without UFs, indicating that these proinflammatory cytokines may impair endometrial receptivity, leading to implantation failure in in vitro fertilization programs. Hormonal treatments using gonadotropin releasing hormone analogs and the selective progesterone receptor modulator ulipristal acetate significantly shrink UFs and improve UF-related symptoms. These compounds can regulate local inflammation in UFs and adjacent myometrium. Controlling and improving local inflammation caused by UFs may represent a novel therapeutic strategy for UFs and potentially improve reproductive outcomes in women with symptomatic UFs.
Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.
Esophageal cancer (EC) is the common malignant tumor with poor survival. The long-term surival rate of patients with advanced EC stages has not been improved with multidisciplinary treatments including surgery and chemotherapy and radiation. Recently, immunotherapy approaches using checkpoint inhibitors (CPI), cancer vaccine, and adoptive T cell therapy have improved survival outcomes of EC patients. The clinical outcomes are associated with expression levels as well as the immunogenicity of neoantigens which arise from soma mutations. Therefore, the identification of immunogenic neoantigens is essential for achieving effective therapies. Recent data published by the Tumor Neoantigen Selection Alliance (TESLA) show that the majority (98%) of predicted neoantigens are lack of immunogenicity and ineffective in activating antitumor immune responses. In our study, we aim to develop a pipeline with both computational prediction tools and experimental validation assays to enhance the accuracy of neoantigen identification.
OBJECTIVES: I. To evaluate the utility of the 6 telephone sessions (low intensity: LiTx) and 8 telephone sessions (high intensity: HiTx) plus Survivorship Booklet designed to educate and improve awareness of the physical and psychological impact of cancer and increase knowledge of appropriate medical and psychosocial resources for women with cervical cancer. II. To evaluate the utility of the telephone sessions (LiTx and HiTx) designed to improve psychological functioning (decrease depression and anxiety) of women with cervical cancer. III. To evaluate the utility of the telephone sessions (LiTx and HiTx) designed to improve social functioning (family support and communication).

OUTLINE: Patients are clinically assigned to 1 of 2 groups. GROUP I: Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet. GROUP II: Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
The invention relates to a traditional Chinese medicine composition for preventing myocardial ischemia. The traditional Chinese medicine composition is extracted from actinidia valvata leaves. The invention also provides a traditional Chinese medicine preparation containing the traditional Chinese medicine composition and applications of the traditional Chinese medicine preparation. For the first time, people find that the composition prepared from actinidia valvata leaf can be used to treat diseases related with myocardial ischemia. The experiment results show that actinidia valvata leaf extract can prominently relieve the symptoms of myocardial ischemia after SD rat coronary artery ligation and has a prominent effect on preventing damages caused by myocardial ischemia. The preparation method has the advantages of simple technology, low cost, safety, effectiveness, and low organic solvent residue, has a wide application prospect, and is capable of generating great social and economic benefits.
Disturbances in phosphate homeostasis are strongly associated with cardiovascular morbidity and mortality. High dietary phosphate intake plays a central role in the development of disturbed phosphate metabolism and is common in persons consuming typical American diets rich in processed and fast foods. An important reason for the high phosphate content of these foods is the widespread use of phosphate-based food additives in the food supply. Phosphate additives are heavily utilized by the food manufacturing industry to enhance the appearance, taste and shelf-life of processed foods, accounting for as much as 50% of total phosphate intake per day. Prior work from our group suggest that high phosphate additive intake has serious cardiovascular consequences. We showed that phosphate excess induces heart disease and inflammation in experimental studies, and associates with heart disease and death independently of classic risk factors in epidemiology studies. Further, we showed that high phosphate additive intake stimulates the secretion of fibroblast growth factor 23 (FGF23), a phosphate-regulatory hormone directly implicated in the pathogenesis of cardiovascular disease. Together, these data strongly suggest that high phosphate additive intake promotes cardiovascular disease, with important potential implications for efforts to reduce disparities in cardiovascular disease. This is because individuals with low socioeconomic status have limited means to purchase healthy foods, resulting in excessive consumption of processed foods rich in phosphate additives. Moreover, low income neighborhoods have a disproportionately high prevalence of individuals with chronic kidney disease and black individuals, both groups that have impaired ability to excrete excess phosphate. Together, these data support our overriding hypothesis that high phosphate additive intake is a novel target for reducing socioeconomic and racial disparities in cardiovascular. We will test this hypothesis in detailed feeding studies of 80 individuals fed standardized meals with low phosphate additive content for 6 weeks. We will investigate the impact of reducing phosphate additive intake on changes in FGF23 levels, inflammatory markers and vascular function, and test for effect modification by race and chronic kidney disease (CKD). The results of these studies will help determine whether high phosphate additive intake is a modifiable risk factor for disparities in cardiovascular disease.
Furosemide is a loop diuretic widely used in the treatment of congestive heart failure and edema. While it can be used for first aid in the presence of heart failure, it has strong side effects, like hyperuricemia. So the aim of this method is to detect which genes or metabolic enzymes are susceptible to the use of furosemide in the first aid of heart failure and other situations and then give risk prediction and pharmacodynamic prediction of furosemic, so that furosemide can play the most effective role in the process of treating the patients. Our method constitutes of three part, namely the designing of the panel, genome comparison and getting the instruction report. In the first part, we searched the essays from PubMed about the gene's mutation about furosemide and then we screened out about 300 articles.The article contains 17 possible mutations, and we combined the discovery from PharmaGKB to integrate human-related genes, and we got 14 possible mutations about the efficacy of furosemide and concluded them into a database named 'dbknowledge'. In the second part, we made detailed analysis of the obtained genetic mutations based on the databases BWA, Picard-tools, GATK, and Annovar through the procedure including mapping, preprocessing, variants calling, variants filtration, annotation and selecting target region to acquire the multiple mutations on expressed region of human beings. Besides, we designed a perl program which could help compare the gene mutations we got to the database we established before. In the third part, we could get the instruction report which includes three parts 'the inspection result', 'detection of related annotation' and 'medical encyclopedia'. This report helps give the risk prediction of the furosemide, which is likely to be very useful in the clinical treatment.
Twenty ALS patients who are independent in their transfer with assistive devise such as walker, cane, or AFO will be offered the opportunity to participate in this study. 20 subjects will be enrolled at Carolinas ALS/Neuromuscular Center at the Carolinas HealthCare System. Eligible subjects will return for 26 sessions, each lasting between 1-2 hours. At Session 1 (4 weeks pre-treatment), assessments of muscle strength, spasticity, gait, and balance will be performed, which will take between 30-60 minutes. At Sessions 2-25, patients will do supported treadmill ambulation training at a very low speed 3 times a week for 6 weeks under the supervision of the physical therapist. Each session will have 30 minutes of direct ambulation with the suspension system and treadmill over a 60 minute period of time. Additionally, at sessions 13 and 26 (4 and 8 weeks post-treatment), the assessments of muscle strength, spasticity, gait, and balance will be repeated. Needle EMG to assess denervation potential will be performed at base line and at the conclusion of the study. The study will last a total of 26 weeks for each patient.
Millions HIV-infected individuals are now receiving life-saving antiretroviral therapy (ART). However, mortality remains high, particularly in resource-limited countries. Chronic HIV-infected individuals demonstrate evidence of persistent immune activation despite ART, which is an independent predictor of mortality in this setting. Given the current absence of an effective HIV vaccine, finding a cure for HIV will have a large impact on the long-term health of treated HIV-infected individuals. The key challenge of HIV eradication strategies is the persistence of a small pool of resting memory CD4+ T cells that harbor latent replication-competent HIV, untouched by current ART. One potential strategy to eliminate this reservoir in a "shock and kill" approach in which latency reactivating agents (LRAs) are used to "shock" the virus out of these cells in order for the host immune response, ART, and/or additional immunomodulatory agents to then kill the virus-expressing cells. The goal of the current study is to evaluate the safety and in vivo biological response to an herbal supplement used in traditional Chinese medicine ("kansui)" that has potent in vitro latency reactivating capabilities. Kansui is an inexpensive, readily available herbal supplement prescribed for thousands of years in traditional Chinese medicine and contains active compounds such as ingenols that have been shown to reverse latency in an animal model. A semi-synthetic form of ingenol has been shown to potently reactivate latent simian immunodeficiency virus (SIV) in rhesus macaques and is currently undergoing early drug development. Though kansui has been studied extensively in traditional Chinese medicine, this herbal supplement has never been evaluated for biologic activity in HIV disease using Western scientific research methods. This pilot clinical trial will generate preliminary results regarding the safety and in vivo biologic activity of kansui. Promising results from this study may allow future larger studies which can evaluate the efficacy of this non-pharmacologic agent in the treatment of HIV disease.
###  Pregnancy Category D 

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue moexipril hydrochloride as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. 

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue moexipril hydrochloride, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to moexipril hydrochloride for hypotension, oliguria, and hyperkalemia (see PRECAUTIONS, Pediatric Use).

No embryotoxic, fetotoxic, or teratogenic effects were seen in rats or in rabbits treated with up to 90.9 and 0.7 times, respectively, the Maximum Recommended Human Dose (MRHD) on a mg/m2 basis.